SMMT
USDSummit Therapeutics Inc. Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$17.780
Máximo
$18.120
Mínimo
$17.370
Volumen
2.88M
Fundamentos de la Empresa
Capitalización de Mercado
13.0B
Industria
Biotecnología
País
United States
Estadísticas de Negociación
Volumen Promedio
4.10M
Bolsa
NGM
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
Summit Therapeutics to Present at Upcoming Investor Conferences
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this year. Members of the
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
Conducted by Akeso, HARMONi-A Represents the First Statistically Significant OS Benefit Achieved in a Phase III Study by an Ivonescimab-Containing Regimen Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the
Guggenheim Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target
Guggenheim analyst Brad Canino reiterates Summit Therapeutics with a Buy and maintains $40 price target.
Summit Therapeutics Raises $500 Million in Private Placement
Fundraise Led by Leading Biopharma Institutional Investors & Insiders $500 Million in Gross & Net Proceeds Raised at Yesterday's Closing Price of $18.74 Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit,"
Barclays Maintains Underweight on Summit Therapeutics, Raises Price Target to $16
Barclays analyst Etzer Darout maintains Summit Therapeutics with a Underweight and raises the price target from $13 to $16.
HC Wainwright & Co. Maintains Buy on Summit Therapeutics, Lowers Price Target to $40
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Summit Therapeutics with a Buy and lowers the price target from $50 to $40.
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
Conference Call to be Held at 8:00am ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, before the
Acciones Relacionadas
PFD
Flaherty & Crumrine Preferred and Income Fund Incorporated
XELAP
Exela Technologies Inc. 6.00% Series B Cumulative Convertible Perpetual Preferred Stock
RLYB
Rallybio Corporation
AAT
American Assets Trust Inc.
VNOM
Viper Energy Inc.
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.